The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by ...

We came across a bearish thesis on DexCom, Inc. on Hunterbrook’s Substack. In this article, we will summarize the bulls’ ...

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

10 analysts have expressed a variety of opinions on DexCom (NASDAQ: DXCM) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A ...

Investing in bespoke processes can sidestep the inefficiencies of ‘lazy artificial intelligence (AI)’ in medical device ...

The chief technology officer and co-founder explained the technology and design choices that went into Biolinq’s device, ...

Walmart will become the first U.S. retailer to sell an over-the-counter continuous glucose monitor in physical stores, as ...

A class action lawsuit has been filed against Dexcom (Nasdaq:DXCM) in the U.S. District Court for the Central District of California.

Analysts have set 12-month price targets for DexCom, revealing an average target of $97.15, a high estimate of $106.00, and a ...